HemoChat

Evidence-Based AI Medical Search

← Back to guidelines
Gastroenterology168 papers

Autoimmune hepatitis

Last edited: 4/14/2026

Overview

Autoimmune hepatitis (AIH) is a chronic inflammatory liver disease characterized by immune-mediated damage to hepatocytes, leading to potential cirrhosis and liver failure if untreated 23.

Diagnosis

  • Clinical Presentation: Variable, from asymptomatic to acute liver failure 2.
  • Laboratory Findings: Elevated liver enzymes, hypergammaglobulinemia, presence of autoantibodies (e.g., ANA, SMA, LKM1) 911.
  • Histological Features: Necroinflammatory lesions in liver biopsy 9.
  • Exclusion Criteria: Viral hepatitis, metabolic disorders, and other causes of liver disease 9.
  • Simplified Criteria: Sex, age, autoantibodies, immunoglobulins, absence of viral hepatitis, and histology 21.

    • Management

  • First-Line Treatment: Corticosteroids (e.g., prednisolone) with or without azathioprine 2313.
  • Adjunctive Therapies: For inadequate response or intolerance, consider second-line agents like mycophenolate mofetil, calcineurin inhibitors (e.g., tacrolimus), or budesonide 13.
  • Monitoring: Regular assessment of liver function tests, autoantibody levels, and liver histology 117.
  • Dose Adjustment: Tailor immunosuppressive therapy based on response and side effects 15.

    • Special Populations

  • Pediatrics: Recognize two types based on autoantibodies (AIH-1 and AIH-2) 14.
  • Pregnancy: Management requires careful consideration of immunosuppressive therapy risks and benefits 25.
  • Comorbidities: Increased risk of Clostridium difficile infection in patients with AIH 23.

    • Key Recommendations

  • Initiate Corticosteroids for Confirmed AIH Diagnosis: Start with prednisolone, typically initiating at 20-40 mg/day, adjusting based on response (Evidence: Strong 23).
  • Add Azathioprine for Maintenance Therapy: Combine with corticosteroids to reduce steroid dependency and improve long-term outcomes (Evidence: Strong 23).
  • Consider Second-Line Agents for Refractory Cases: Evaluate and switch to agents like mycophenolate mofetil or calcineurin inhibitors for inadequate response or intolerance to first-line therapy (Evidence: Moderate 13).
  • Regular Monitoring Essential: Include periodic liver function tests, autoantibody levels, and clinical assessment to guide therapy adjustments (Evidence: Moderate 117).
  • Special Attention in Pediatric Patients: Tailor diagnosis and management considering autoantibody types specific to pediatric AIH (Evidence: Moderate 14).

    • References

    1 Pan C, Zhou X, Wang Y, Wu Y, Han Q, Cui X. Autoimmune hepatitis associated with statins: a retrospective study of pharmacovigilance databases and review of the literature. Expert opinion on drug safety 2026. link 2 . EASL Clinical Practice Guidelines on the management of autoimmune hepatitis. Journal of hepatology 2025. link 3 Gleeson D, Bornand R, Brownlee A, Dhaliwal H, Dyson JK, Hails J et al.. British Society of Gastroenterology guidelines for diagnosis and management of autoimmune hepatitis. Gut 2025. link 4 Khanna R, Lal BB, Sood V, Alam S, Nagral A, Ravindranath A et al.. Autoimmune hepatitis in children: Guidelines of the Indian Society of Pediatric Gastroenterology, Hepatology, and Nutrition (ISPGHAN). Hepatology international 2025. link 5 Ye W, Ding Y, Li M, Tian Z, Wang S, Liu Z. Drug-induced autoimmune-like hepatitis: A disproportionality analysis based on the FAERS database. PloS one 2025. link 6 Zhu BK, Chen SY, Li X, Huang SY, Luo ZY, Zhang W. Real-world pharmacovigilance study of drug-induced autoimmune hepatitis from the FAERS database. Scientific reports 2025. link 7 Kochhar S, Assis DN, Mack C, Izurieta HS, Muratori L, Munoz A et al.. Autoimmune hepatitis: Brighton Collaboration case definition and guidelines for data collection, analysis, and presentation of immunisation safety data. Vaccine 2024. link 8 Díez Ruiz S, Quiñones Castro R, Alcoba Vega L, Martín Izquierdo A, González Puente I, Rodríguez Martín L et al.. Autoimmune hepatitis after SARS-C¬¬oV-2 vaccination. Revista espanola de enfermedades digestivas 2023. link 9 Lemoinne S, Heurgue A, Bouzbib C, Hanslik B, Gournay J, Nguyen-Khac E et al.. Non-invasive diagnosis and follow-up of autoimmune hepatitis. Clinics and research in hepatology and gastroenterology 2022. link 10 Jo HI, Kim M, Yoo JJ, Kim SG, Kim YS, Chin S. Acute Hepatitis A-Induced Autoimmune Hepatitis: A Case Report and Literature Review. Medicina (Kaunas, Lithuania) 2022. link 11 Ramonet M, Ramirez-Rodriguez N, Álvarez Chávez F, Arregui MC, Boldrini G, Botero Osorio V et al.. Autoimmune hepatitis in pediatrics, a review by the Working Group of the Latin American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. Archivos argentinos de pediatria 2022. link 12 Llovet LP, Gratacós-Ginès J, Téllez L, Gómez-Outomuro A, Navascués CA, Riveiro-Barciela M et al.. Noninvasive Prediction of Outcomes in Autoimmune Hepatitis-Related Cirrhosis. Hepatology communications 2022. link 13 Lohse AW, Sebode M, Jørgensen MH, Ytting H, Karlsen TH, Kelly D et al.. Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group. Journal of hepatology 2020. link 14 Mieli-Vergani G, Vergani D, Baumann U, Czubkowski P, Debray D, Dezsofi A et al.. Diagnosis and Management of Pediatric Autoimmune Liver Disease: ESPGHAN Hepatology Committee Position Statement. Journal of pediatric gastroenterology and nutrition 2018. link 15 Eugene C. Comment on the British Society of Gastroenterology guidelines for management of autoimmune hepatitis (part 2). Clinics and research in hepatology and gastroenterology 2012. link 16 Eugène C. Comment on the British Society of Gastroenterology guidelines for management of autoimmune hepatitis (part 1). Clinics and research in hepatology and gastroenterology 2012. link 17 Czaja AJ. Advances in the current treatment of autoimmune hepatitis. Digestive diseases and sciences 2012. link 18 Maggiore G, Sciveres M, Fabre M, Gori L, Pacifico L, Resti M et al.. Giant cell hepatitis with autoimmune hemolytic anemia in early childhood: long-term outcome in 16 children. The Journal of pediatrics 2011. link 19 Ramakrishna J, Johnson AR, Banner BF. Long-term minocycline use for acne in healthy adolescents can cause severe autoimmune hepatitis. Journal of clinical gastroenterology 2009. link 20 Tabak F, Ozdemir F, Tabak O, Erer B, Tahan V, Ozaras R. Autoimmune hepatitis induced by the prolonged hepatitis A virus infection. Annals of hepatology 2008. link 21 Hennes EM, Zeniya M, Czaja AJ, Parés A, Dalekos GN, Krawitt EL et al.. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology (Baltimore, Md.) 2008. link 22 Ford TJ, Dillon JF. Minocycline hepatitis. European journal of gastroenterology & hepatology 2008. link 23 Vanjak D, Girault G, Branger C, Rufat P, Valla DC, Fantin B. Risk factors for Clostridium difficile infection in a hepatology ward. Infection control and hospital epidemiology 2007. link 24 Czaja AJ, Bianchi FB, Carpenter HA, Krawitt EL, Lohse AW, Manns MP et al.. Treatment challenges and investigational opportunities in autoimmune hepatitis. Hepatology (Baltimore, Md.) 2005. link 25 Strassburg CP, Manns MP. Transition of care between paediatric and adult gastroenterology. Autoimmune hepatitis. Best practice & research. Clinical gastroenterology 2003. link00015-5) 26 Teitelbaum JE, Perez-Atayde AR, Cohen M, Bousvaros A, Jonas MM. Minocycline-related autoimmune hepatitis: case series and literature review. Archives of pediatrics & adolescent medicine 1998. link 27 Banerjee AK, Grainger SL, Davies DR, Thompson RP. Active chronic hepatitis and febrile panniculitis. Gut 1989. link 28 Moriwaki Y, Maebo A, Yamade W, Yamamoto T, Amuro Y, Hada T et al.. Autoimmune hepatitis or hepatic involvement in SLE?--A case report. Gastroenterologia Japonica 1987. link

    Original source

    1. [1]
      Autoimmune hepatitis associated with statins: a retrospective study of pharmacovigilance databases and review of the literature. — Pan C, Zhou X, Wang Y, Wu Y, Han Q, Cui X Expert opinion on drug safety (2026)
    2. [2]
      EASL Clinical Practice Guidelines on the management of autoimmune hepatitis. Journal of hepatology (2025)
    3. [3]
      British Society of Gastroenterology guidelines for diagnosis and management of autoimmune hepatitis. — Gleeson D, Bornand R, Brownlee A, Dhaliwal H, Dyson JK, Hails J et al. Gut (2025)
    4. [4]
      Autoimmune hepatitis in children: Guidelines of the Indian Society of Pediatric Gastroenterology, Hepatology, and Nutrition (ISPGHAN). — Khanna R, Lal BB, Sood V, Alam S, Nagral A, Ravindranath A et al. Hepatology international (2025)
    5. [5]
      Drug-induced autoimmune-like hepatitis: A disproportionality analysis based on the FAERS database. — Ye W, Ding Y, Li M, Tian Z, Wang S, Liu Z PloS one (2025)
    6. [6]
      Real-world pharmacovigilance study of drug-induced autoimmune hepatitis from the FAERS database. — Zhu BK, Chen SY, Li X, Huang SY, Luo ZY, Zhang W Scientific reports (2025)
    7. [7]
      Autoimmune hepatitis: Brighton Collaboration case definition and guidelines for data collection, analysis, and presentation of immunisation safety data. — Kochhar S, Assis DN, Mack C, Izurieta HS, Muratori L, Munoz A et al. Vaccine (2024)
    8. [8]
      Autoimmune hepatitis after SARS-C¬¬oV-2 vaccination. — Díez Ruiz S, Quiñones Castro R, Alcoba Vega L, Martín Izquierdo A, González Puente I, Rodríguez Martín L et al. Revista espanola de enfermedades digestivas (2023)
    9. [9]
      Non-invasive diagnosis and follow-up of autoimmune hepatitis. — Lemoinne S, Heurgue A, Bouzbib C, Hanslik B, Gournay J, Nguyen-Khac E et al. Clinics and research in hepatology and gastroenterology (2022)
    10. [10]
      Acute Hepatitis A-Induced Autoimmune Hepatitis: A Case Report and Literature Review. — Jo HI, Kim M, Yoo JJ, Kim SG, Kim YS, Chin S Medicina (Kaunas, Lithuania) (2022)
    11. [11]
      Autoimmune hepatitis in pediatrics, a review by the Working Group of the Latin American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. — Ramonet M, Ramirez-Rodriguez N, Álvarez Chávez F, Arregui MC, Boldrini G, Botero Osorio V et al. Archivos argentinos de pediatria (2022)
    12. [12]
      Noninvasive Prediction of Outcomes in Autoimmune Hepatitis-Related Cirrhosis. — Llovet LP, Gratacós-Ginès J, Téllez L, Gómez-Outomuro A, Navascués CA, Riveiro-Barciela M et al. Hepatology communications (2022)
    13. [13]
      Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group. — Lohse AW, Sebode M, Jørgensen MH, Ytting H, Karlsen TH, Kelly D et al. Journal of hepatology (2020)
    14. [14]
      Diagnosis and Management of Pediatric Autoimmune Liver Disease: ESPGHAN Hepatology Committee Position Statement. — Mieli-Vergani G, Vergani D, Baumann U, Czubkowski P, Debray D, Dezsofi A et al. Journal of pediatric gastroenterology and nutrition (2018)
    15. [15]
      Comment on the British Society of Gastroenterology guidelines for management of autoimmune hepatitis (part 2). — Eugene C Clinics and research in hepatology and gastroenterology (2012)
    16. [16]
      Comment on the British Society of Gastroenterology guidelines for management of autoimmune hepatitis (part 1). — Eugène C Clinics and research in hepatology and gastroenterology (2012)
    17. [17]
      Advances in the current treatment of autoimmune hepatitis. — Czaja AJ Digestive diseases and sciences (2012)
    18. [18]
      Giant cell hepatitis with autoimmune hemolytic anemia in early childhood: long-term outcome in 16 children. — Maggiore G, Sciveres M, Fabre M, Gori L, Pacifico L, Resti M et al. The Journal of pediatrics (2011)
    19. [19]
      Long-term minocycline use for acne in healthy adolescents can cause severe autoimmune hepatitis. — Ramakrishna J, Johnson AR, Banner BF Journal of clinical gastroenterology (2009)
    20. [20]
      Autoimmune hepatitis induced by the prolonged hepatitis A virus infection. — Tabak F, Ozdemir F, Tabak O, Erer B, Tahan V, Ozaras R Annals of hepatology (2008)
    21. [21]
      Simplified criteria for the diagnosis of autoimmune hepatitis. — Hennes EM, Zeniya M, Czaja AJ, Parés A, Dalekos GN, Krawitt EL et al. Hepatology (Baltimore, Md.) (2008)
    22. [22]
      Minocycline hepatitis. — Ford TJ, Dillon JF European journal of gastroenterology & hepatology (2008)
    23. [23]
      Risk factors for Clostridium difficile infection in a hepatology ward. — Vanjak D, Girault G, Branger C, Rufat P, Valla DC, Fantin B Infection control and hospital epidemiology (2007)
    24. [24]
      Treatment challenges and investigational opportunities in autoimmune hepatitis. — Czaja AJ, Bianchi FB, Carpenter HA, Krawitt EL, Lohse AW, Manns MP et al. Hepatology (Baltimore, Md.) (2005)
    25. [25]
      Transition of care between paediatric and adult gastroenterology. Autoimmune hepatitis. — Strassburg CP, Manns MP Best practice & research. Clinical gastroenterology (2003)
    26. [26]
      Minocycline-related autoimmune hepatitis: case series and literature review. — Teitelbaum JE, Perez-Atayde AR, Cohen M, Bousvaros A, Jonas MM Archives of pediatrics & adolescent medicine (1998)
    27. [27]
      Active chronic hepatitis and febrile panniculitis. — Banerjee AK, Grainger SL, Davies DR, Thompson RP Gut (1989)
    28. [28]
      Autoimmune hepatitis or hepatic involvement in SLE?--A case report. — Moriwaki Y, Maebo A, Yamade W, Yamamoto T, Amuro Y, Hada T et al. Gastroenterologia Japonica (1987)
    Share:TwitterRedditLinkedIn

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG